NCT05230953View on ClinicalTrials.gov

Fourth COVID-19 Vaccine Dose- mRNA1273

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

July 4, 2024

Study Completion Date

July 4, 2024

Conditions
COVID-19 Pandemic
Interventions
BIOLOGICAL

mRNA1273 vaccine

fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM

Trial Locations (1)

5265601

Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV